Continuation of fluoropyrimidine treatment with S-1 after cardiotoxicity on capecitabine- or 5-fluorouracil-based therapy in patients with solid tumours: a multicentre retrospective observational cohort study

BACKGROUND: Capecitabine- or 5-fluorouracil (5-FU)-based chemotherapy is widely used in many solid tumours, but is associated with cardiotoxicity. S-1 is a fluoropyrimidine with low rates of cardiotoxicity, but evidence regarding the safety of switching to S-1 after 5-FU- or capecitabine-associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Osterlund, P., Kinos, S., Pfeiffer, P., Salminen, T., Kwakman, J.J.M., Frödin, J.-E., Shah, C.H., Sorbye, H., Ristamäki, R., Halonen, P., Soveri, L.M., Heervä, E., Ålgars, A., Bärlund, M., Hagman, H., McDermott, R., O’Reilly, M., Röckert, R., Liposits, G., Kallio, R., Flygare, P., Teske, A.J., van Werkhoven, E., Punt, C.J.A., Glimelius, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291631/
https://www.ncbi.nlm.nih.gov/pubmed/35798468
http://dx.doi.org/10.1016/j.esmoop.2022.100427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291631/
https://www.ncbi.nlm.nih.gov/pubmed/35798468
http://dx.doi.org/10.1016/j.esmoop.2022.100427

Ejemplares similares